Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in ...

CRISPR Therapeutics AG CRSP shares rallied 9.6% in the last trading session to close at $60.08. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025. ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...

Names including Kohls, Plug Power, and Mara Holdings round out the list of the market's top 10 most-shorted stocks.

Is CRISPR Therapeutics a good biotech stock to buy on the recent dip? To answer that, we need to understand what its new therapy can and can't do. What Casgevy from CRISPR Therapeutics does.

CRISPR Therapeutics (CRSP 0.79%) could revolutionize the healthcare sector, and that has made CRISPR stock a hot buy. While the company isn't profitable yet, it had its first treatment ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...

CRISPR Therapeutics stock has a market cap of $4.2 billion, which doesn't seem terribly high for a company that could be on the cusp of an approval for an expensive, life-changing treatment .

CRISPR Therapeutics' product approval -- the world's first for a CRISPR-based gene editing therapy -- is making headlines and turning investors' attention to this exciting technology.